MX2023013715A - Regímenes de dosis de ecubectedina. - Google Patents

Regímenes de dosis de ecubectedina.

Info

Publication number
MX2023013715A
MX2023013715A MX2023013715A MX2023013715A MX2023013715A MX 2023013715 A MX2023013715 A MX 2023013715A MX 2023013715 A MX2023013715 A MX 2023013715A MX 2023013715 A MX2023013715 A MX 2023013715A MX 2023013715 A MX2023013715 A MX 2023013715A
Authority
MX
Mexico
Prior art keywords
dosage regimens
ecubectedin
ester
compound
formula
Prior art date
Application number
MX2023013715A
Other languages
English (en)
Spanish (es)
Inventor
Carmen Kahatt
Arturo Soto
Pilar Lardelli
Cristian Fernandez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2023013715A publication Critical patent/MX2023013715A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023013715A 2021-05-19 2022-05-19 Regímenes de dosis de ecubectedina. MX2023013715A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21382455 2021-05-19
PCT/EP2022/063653 WO2022243482A1 (en) 2021-05-19 2022-05-19 Dosage regimens for ecubectedin

Publications (1)

Publication Number Publication Date
MX2023013715A true MX2023013715A (es) 2024-03-26

Family

ID=76197383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013715A MX2023013715A (es) 2021-05-19 2022-05-19 Regímenes de dosis de ecubectedina.

Country Status (11)

Country Link
US (1) US20240277705A1 (cg-RX-API-DMAC7.html)
EP (1) EP4340841A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521122A (cg-RX-API-DMAC7.html)
KR (1) KR20240009437A (cg-RX-API-DMAC7.html)
CN (1) CN117295499A (cg-RX-API-DMAC7.html)
AU (1) AU2022277799A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218171A1 (cg-RX-API-DMAC7.html)
IL (1) IL308389A (cg-RX-API-DMAC7.html)
MX (1) MX2023013715A (cg-RX-API-DMAC7.html)
TW (1) TW202313039A (cg-RX-API-DMAC7.html)
WO (1) WO2022243482A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
WO2025228595A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
TW202547503A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之pm14和拓樸異構酶i抑制劑的組合
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
EP2786755A3 (en) * 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
WO2022243482A1 (en) 2022-11-24
TW202313039A (zh) 2023-04-01
CA3218171A1 (en) 2022-11-24
IL308389A (en) 2024-01-01
EP4340841A1 (en) 2024-03-27
AU2022277799A1 (en) 2023-12-21
CN117295499A (zh) 2023-12-26
US20240277705A1 (en) 2024-08-22
KR20240009437A (ko) 2024-01-22
JP2024521122A (ja) 2024-05-28

Similar Documents

Publication Publication Date Title
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MX2025000105A (es) Inhibidor de kras g12c para el tratamiento del cancer
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12022551574A1 (en) Egfr inhibitors
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EA202193015A1 (ru) Ингибиторы cdk
PH12021552482A1 (en) Compounds targeting prmt5
MX2024005855A (es) Procedimientos para tratar el cancer.
MX2024000230A (es) Inhibidores de cdk2.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
WO2020033838A3 (en) Treatment of egfr-mutant cancer
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
ZA202401684B (en) Novel parp7 inhibitor and use thereof
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
EP4233865A3 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
MX2025001982A (es) Inhibidores de kif18a y usos de estos
PH12021552513A1 (en) Pyrrole compounds
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2024002409A (es) Terapias contra el cancer.
PH12021552263A1 (en) Macrocyclic compounds as sting agonists